Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer enrolled in the phase 3 KEYNOTE-756 trial.

Related Keywords

Baylor University ,Texas ,United States ,San Antonio ,China ,Dallas ,Samsung Bioepis ,Joyce Oshaughnessy ,Daiichi Sankyo ,Glaxosmithkline ,Fishawack Health ,Novartis ,Pierre Fabre Pharmaceuticals ,Genentech ,Merck Sharp Dohme ,Aptitude Health ,Astrazeneca ,Abbvie Inc ,Pfizer ,Breast Cancer Research Program At Texas Oncology ,Gilead Sciences ,Antonio Breast Cancer Symposium ,Eastern Europe ,Celebrating Women Chair ,Breast Cancer Research ,Baylor University Medical Center ,Breast Cancer Research Program ,Texas Oncology ,Carrick Therapeutics ,Loxo Oncology ,Puma Biotechnology ,Merck Sharp ,Neoadjuvant Pembrolizumab ,Pembrolizumab ,Immunotherapy ,Her Breast Cancer ,Breast Cancer ,Keynote 756 Trial ,Sabcs ,San Antonio Breast Cancer Symposium ,Esmo Congress ,Us Oncology ,Joyceo Shaughnessy ,D ,